Arcus Biosciences, Inc.

Aug 5, 2026

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences reported its financial results for the second quarter of 2026, showcasing a strong performance. The company also provided an update on its clinical pipeline, emphasizing its commitment to developing innovative therapies for cancer and autoimmune diseases. A recent publication in Nature further underscores their research efforts.

Jul 22, 2026

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients

Arcus Biosciences has entered into a clinical supply agreement with AVEO Oncology to assess the efficacy of casdatifan, a small-molecule HIF-2α inhibitor, in combination with tivozanib for patients with advanced kidney cancer. This collaboration aims to explore innovative treatment options for this patient population.

Jul 22, 2026

Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Arcus Biosciences and Summit Therapeutics have announced a clinical trial collaboration to evaluate the efficacy of casdatifan combined with ivonescimab in treating kidney cancer. This partnership aims to leverage their respective strengths in developing innovative cancer therapies. The trial seeks to address significant unmet medical needs in oncology.

Jul 21, 2026

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates

Arcus Biosciences will hold a conference call on August 5, 2026, to discuss its second-quarter financial results and updates on its drug pipeline. The call is scheduled for 1:30 PM PT / 4:30 PM ET. This event will provide stakeholders with important insights into the company's performance and future directions.

Jul 1, 2026

New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan

A new study published in Nature discusses the relationship between clinical activity and HIF-2a biology in advanced kidney cancer patients treated with Casdatifan. This research may provide insights into the efficacy of Casdatifan in this patient population. Further details about the findings and implications are yet to be disclosed.

Jul 1, 2026

▼ -6.2%on this newsshared move

From Target to Translation: Revealing the Mechanism Behind HIF-2<span style= "font-family: Georgia, serif; text-transform: none;">α</span> Inhibition in Kidney Cancer

A recent study published in Nature highlights the efficacy of casdatifan, a HIF-2α inhibitor, in treating kidney cancer. The research connects tumor biology and blood biomarkers to clinical outcomes, demonstrating that deeper suppression of the HIF-2α pathway correlates with improved patient responses. This study represents a significant advancement in understanding how targeting HIF-2α can lead to better treatment outcomes for kidney cancer patients.

Jun 3, 2026

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences has announced a clinical trial collaboration and supply agreement to evaluate Casdatifan in combination with a PD-L1/VEGF-A bispecific immunomodulator for treating kidney cancer. This collaboration aims to explore the efficacy of this combination therapy in clinical settings. Further details on the trial design and expected outcomes were not disclosed.

May 26, 2026

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Arcus Biosciences is scheduled to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. This event is a significant gathering for industry leaders and stakeholders. Further details about their presentation or topics of discussion have not been disclosed in the article.

May 5, 2026

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences has reported its financial results for the first quarter of 2026 and provided an update on its pipeline. The article highlights the company's ongoing efforts in drug development and financial performance. However, specific details regarding the financial results and pipeline advancements are not disclosed in the text.

Apr 21, 2026

▲ +7.8%on this news

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates

Arcus Biosciences will host a conference call on May 5, 2026, to discuss its first-quarter financial results and pipeline updates. The call will provide insights into the company's progress in developing therapies for cancer and autoimmune diseases. Investors can join via phone or online, with a replay available post-event.

Arcus Biosciences Announces New Employment Inducement Grants - March 24, 2026

Arcus Biosciences has granted employment inducement equity awards to two new employees, totaling 7,050 stock options and 3,550 restricted stock units. The options were priced at $21.41 per share, reflecting the closing price on March 23, 2026. These awards were made under the company's 2020 Inducement Plan, approved by the Board of Directors.

Mar 24, 2026

▼ -5.4%on this newsshared move

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences has announced new employment inducement grants. The details surrounding the grants and their implications for the company were not disclosed in the article. This announcement may indicate the company's efforts to attract talent amidst a competitive market.

Feb 26, 2026

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

Arcus Biosciences reported its financial results for Q4 and full year 2025, highlighting the promising profile of casdatifan as a leading HIF-2a inhibitor. The company is focused on advancing its Phase 3 study, PEAK-1, and aims to establish casdatifan as a standard-of-care therapy for clear cell renal cell carcinoma. With a robust pipeline and financial stability, Arcus is well-positioned for future growth.

Feb 24, 2026

▲ +7.1%on this newsshared move

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

Arcus Biosciences announced promising new data for casdatifan, a HIF-2a inhibitor, showing a progression-free survival of 15.1 months in late-line metastatic clear cell renal cell carcinoma patients. The data, derived from the Phase 1/1b ARC-20 study, indicated a 45% confirmed response rate. The safety profile was manageable, with no unexpected safety signals reported.

Feb 12, 2026

▼ -6.6%on this news

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

Arcus Biosciences will host a conference call on February 25, 2026, to discuss its financial results and pipeline updates for the year ended December 31, 2025. The call will be accessible via phone and online webcast. The company focuses on developing differentiated therapies for cancer and autoimmune diseases, advancing multiple investigational medicines into clinical trials.

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Arcus Biosciences has reported its financial results for Q3 2025, highlighting notable advancements in its pipeline. The company’s lead candidate, casdatifan, achieved a median progression-free survival of 12.2 months in late-line kidney cancer. Additionally, Arcus unveiled new research programs targeting inflammatory and autoimmune diseases while maintaining a strong cash position of $841 million. Data readouts from key studies are anticipated throughout 2026, further informing the efficacy of its treatment candidates.

Aug 6, 2025

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

Arcus Biosciences has reported its second-quarter financial results for 2025, highlighting a robust pipeline including successful initiations for clinical trials of casdatifan in metastatic clear cell renal cell carcinoma (ccRCC). The company has substantial financial resources with $927 million in cash, which it plans to utilize to support ongoing projects. Initial data from the ARC-20 study indicates promising response rates, while the company is positioned to present more mature data later this year and in 2026. Despite increased R&D expenses attributed to ongoing projects, Arcus anticipates sufficient funding to sustain its operations and development efforts moving forward.

Jun 2, 2025

Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg

Arcus Biosciences has reported updated data on its kidney cancer drug casdatifan, showing an increased response rate of 46% in a Phase I/Ib trial. The drug, combined with Exelixis' Cabometyx, demonstrated no significant overlapping toxicity. Analysts express optimism about the results, while Arcus plans to initiate a Phase III trial focusing on progression-free survival. However, Gilead's decision to pass on licensing the drug raises concerns.

May 19, 2025

Deep Dive: Checkpoint Inhibitors at a Crossroads

Checkpoint inhibitors are at a pivotal moment in immuno-oncology, with mixed results from recent trials. While some therapies like relatlimab and ivonescimab show promise, many others, particularly targeting TIGIT, have faced setbacks. The market is projected to grow significantly, but challenges remain in improving response rates and ensuring trial results are applicable to broader populations.

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Arcus Biosciences reported its financial results for Q1 2025 and provided an update on its pipeline, highlighting several upcoming data presentations and clinical studies. The company has positioned itself well with $1.0 billion in cash, which it believes will support its development plans for casdatifan and other investigational therapies. Significant data from the Phase 1 study of casdatifan plus cabozantinib is expected to be presented at the 2025 ASCO Annual Meeting. However, the company also faced a dramatic decrease in revenue and a notable increase in net loss compared to the previous year.

Combining for Change in Kidney Cancer

The article discusses the challenges and advancements in treating metastatic kidney cancer, highlighting the personal story of Leah, a kidney cancer patient. It emphasizes the need for innovative treatment approaches, particularly combination therapies that target multiple biological pathways. The article also underscores the importance of advocacy for increased research funding to improve survival rates for patients with metastatic disease.

Feb 25, 2025

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences reported its fourth-quarter and full-year 2024 financial results, highlighting a financial position bolstered by $150 million in recent financing. The company presented promising data from its Phase 1 AR-C20 study, showing that casdatifan demonstrated improved progression-free survival and response rates compared to existing HIF-2a therapies. Additionally, Arcus plans to initiate the Phase 3 PEAK-1 study in 2025, focusing on the efficacy of casdatifan in combination with cabozantinib in patients with clear cell renal cell carcinoma. The company is well-positioned for future growth with substantial cash reserves for developmental and operational needs.

Nov 6, 2024

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update Data from the Phase 1 1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Sympo

Arcus Biosciences reported its financial results for the third quarter of 2024 and provided updates on its clinical pipeline. Key highlights include promising outcomes from the Phase 1b ARC-20 study of casdatifan, showing a 34% objective response rate in ccRCC patients. Additionally, a collaboration agreement with AstraZeneca aims to evaluate casdatifan in new settings. The company maintains strong financial health with $1.1 billion in available resources to support ongoing and future clinical trials.

Oct 7, 2024

TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO

At the 2024 ESMO Congress, iTeos and GSK presented positive Phase II results for their anti-TIGIT therapy, belrestotug, combined with Jemperli, showing a 60% response rate in NSCLC patients. Despite previous setbacks in the TIGIT space, this data indicates a potential shift towards effective treatments for patients who do not respond to existing therapies. The ongoing research and development in this area suggest a cautious optimism for future advancements.

From Paper to Pill

Arcus's investigational drug, casdatifan, targets HIF-2α to inhibit cancer growth. It has shown promising antitumor activity in early clinical trials for clear cell renal cell carcinoma (ccRCC). The drug is designed to maintain a favorable side effect profile, making it suitable for combination therapies. Ongoing studies aim to optimize its use in treating kidney cancer.

Aug 8, 2024

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update Data from the casdatifan 100 mg expansion cohort of ARC-20, a Phase 1 1b study in clear cell renal cell carcinoma (ccRCC), ar

Arcus Biosciences reported its financial results for the second quarter of 2024, highlighting a robust cash position of $1 billion, sufficient to fund operations into 2027. The company is advancing multiple clinical-stage programs, including the upcoming data presentations from its casdatifan cohort and the start of the Phase 3 PEAK-1 study. They also completed enrollment for the STAR-221 study evaluating domvanalimab. Despite a reported net loss of $93 million for the quarter, Arcus remains optimistic about its pipeline's potential and strategic collaborations.

May 23, 2024

ARC-9 A Randomized Study to Evaluate Etrumadenant Based Treatment Combinations in Previously Treated Metastatic Colorectal Cancer (mCRC) Authors Zev A. Wainberg 1 , Sae-Won Han 2 , Soohyeon Lee 3 , Keun-Wook Lee 4 , Scot

The ARC-9 trial investigated the efficacy of Etrumadenant in combination with chemo immunotherapy for previously treated metastatic colorectal cancer (mCRC). Results indicated a significant improvement in both progression-free survival and overall survival compared to the regorafenib treatment in patients with refractory mCRC. The treatment showed an acceptable safety profile without unexpected toxicities, suggesting a promising new option for patients who have exhausted existing therapies. Further investigations are warranted due to the clinically meaningful efficacy demonstrated in the trial.

Addressing Adenosine: Immunotherapy in the Tumor Microenvironment

Arcus is advancing etrumadenant, an investigational drug targeting the adenosine axis, which is prevalent in tumors. Recent Phase II trials showed that etrumadenant, combined with chemotherapy and immunotherapy, improved survival rates for patients with metastatic colorectal cancer. The drug's development involved meticulous design to ensure selectivity and potency, minimizing side effects.

May 8, 2024

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update Arcus data will be disclosed in two oral presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Arcus Biosciences reported its first-quarter 2024 financial results, highlighting a significant increase in cash reserves, which now total $1.1 billion, providing financial stability into 2027. The company also provided an update on its clinical pipeline, announcing two presentations at the upcoming ASCO Annual Meeting. These presentations aim to showcase key data on treatments for various cancers, including gastric and colorectal cancers. Despite a reported net loss of $4 million, the overall outlook remains positive with robust ongoing development in late-stage oncology programs.

Feb 21, 2024

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to thei

Arcus Biosciences reported its financial results for Q4 and full year 2023, highlighting a new $320 million equity investment from Gilead. The company aims to address high unmet medical needs through its clinical programs, including promising data for its HIF-2a inhibitor, casdatifan. With $1.2 billion in cash reserves projected to support operations until 2027, Arcus is set to accelerate its late-stage studies. However, the discontinuation of a Phase 3 trial raises concerns about regulatory timelines and resource management.

Jan 30, 2024

Gilead Expands Arcus Collaboration with $320M Equity Investment

Gilead Sciences has increased its stake in Arcus Biosciences to 33% through a $320 million equity investment. This amendment to their collaboration will prioritize the development of domvanalimab for lung and gastrointestinal cancers, while halting the ARC-10 study. The investment is expected to support Arcus's pipeline and enhance decision-making within the partnership.

Jan 29, 2024

Gilead Contacts Jacquie Ross, Investors investor_relations gilead.com Meaghan Smith, Media public_affairs gilead.com Arcus Contacts Pia Eaves, Investors peaves arcusbio.com , (617) 459-2006 Holli Kolkey, Media hkolkey ar

Gilead Sciences and Arcus Biosciences have announced an amendment to their collaboration agreement alongside a significant $320 million equity investment by Gilead, increasing its ownership stake in Arcus to 33%. This strategic investment aims to accelerate joint development programs focused on cancer treatment, notably with the domvanalimab program. The collaboration will prioritize several Phase 3 trials, while certain studies like ARC-10 will be discontinued. This move reflects Gilead's confidence in the TIGIT pathway and the potential of their combined therapeutic approaches.

Jan 10, 2024

The Fc-silent Treatment: Pursuing a Known Target in a New Way

Arcus is developing an Fc-silent anti-TIGIT antibody aimed at enhancing cancer immunotherapy. This approach seeks to combine the antibody with other treatments while minimizing potential side effects. Early preclinical studies show that this combination may improve anti-tumor immunity without depleting beneficial immune cells. Phase 2 studies have reported encouraging safety and efficacy results.

Nov 27, 2023

“Cricket is Life in a Nutshell”: Arcus Executive Arun Tholudur Talks Longtime Passion for Cricket, How it Intersects with Drug Development

Arun Tholudur, SVP at Arcus, shares his lifelong passion for cricket and how it informs his work in drug development. He highlights the parallels between cricket and life, emphasizing teamwork and patience. Tholudur has represented the USA in international tournaments, showcasing the sport's growing presence in the US, particularly among immigrant communities.

Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update Data were presented from the ongoing EDGE-Gastric Phase 2 study in first-line upper GI cancers at the Annual Meeting of the Am

Arcus Biosciences reported its third quarter 2023 financial results, highlighting significant progress in its cancer pipeline. The company presented encouraging early data from the Phase 2 EDGE-Gastric study for domvanalimab, indicating potential as a leading anti-TIGIT therapy for upper GI cancers. Financially, Arcus holds $950 million in cash and equivalents, positioning it well for ongoing development through at least 2026. Additionally, updates on other drug candidates, including AB521 and quemliclustat, are anticipated in early 2024.

Gilead, Arcus Anti-TIGIT Combo Gets Phase II Win in Upper GI Cancers

Gilead Sciences and Arcus Biosciences announced positive Phase II results for their combination therapy targeting upper gastrointestinal cancers. The treatment demonstrated an overall response rate of 59% and a six-month progression-free survival rate of 77%. The therapy was well tolerated, with no serious adverse events reported. Further data will be available in the second half of 2024.

Sep 5, 2023

Why Biopharma Companies Buy Stock in One Another

Gilead Sciences has recently made significant equity investments in AlloVir and Arcus Biosciences, reflecting a trend of biopharma companies purchasing stock in one another. These investments can strengthen partnerships, diversify portfolios, and enhance credibility. However, the current economic climate has made such transactions less frequent, with many firms struggling financially post-pandemic.

Aug 7, 2023

Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update • Presented data from the ongoing ARC-7 Phase 2 trial in non-small cell lung cancer at American Society of Clinical On

Arcus Biosciences reported its financial results for Q2 2023 and provided updates on key clinical trials. The company presented encouraging data from the ongoing ARC-7 Phase 2 trial of domvanalimab for non-small cell lung cancer. It initiated the dose-expansion phase of the ARC-20 study for AB521 in renal cell carcinoma and plans to present additional data from multiple trials in early 2024. Despite some setbacks in the development of etrumadenant for prostate cancer, Arcus maintains a solid financial position with $1 billion in cash.

Jun 3, 2023

ASCO: Gilead and Arcus’s Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates

The article highlights concerns regarding a cancer immunotherapy combination from Gilead and Arcus, particularly focusing on lower survival rates. This news has sparked scrutiny within the medical community. Additionally, the article was removed from the BioSpace website due to a lack of editorial review before publication.

May 9, 2023

Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update • Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastroi

Arcus Biosciences has reported its financial results for the first quarter of 2023, highlighting the advancement of multiple clinical trials, including four Phase 3 studies of its drug domvanalimab. The company is well-funded with $1.0 billion in cash, enabling it to sustain operations through 2026. Moreover, Arcus is set to initiate three new drug candidates into clinical trials by early 2024. However, the firm also reported a net loss of $80 million and rising R&D expenses, signaling ongoing financial pressures during its pipeline expansion.

Feb 28, 2023

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update • At the American Society of Clinical Oncology (ASCO) Plenary session in December 2022, interim data wer

Arcus Biosciences has reported its fourth-quarter and full-year 2022 financial results, highlighting progress in its clinical pipeline aimed at cancer treatments. The company presented interim data from the ARC-7 study, showing promising efficacy of the domvanalimab combination therapy. Arcus also initiated several new clinical studies, expecting to release more data about their drug candidates throughout 2023. With substantial financial backing, the company is well-positioned for future growth in the oncology space.

Nov 4, 2022

Arcus and Gilead Make Major Amendment to Phase III NSCLC Trial - Updated

Arcus Biosciences announced a modification to its ARC-10 Phase III trial in collaboration with Gilead Sciences, simplifying the study by removing the chemotherapy arm. The trial will now compare the combination of domvanalimab and zimberelimab against Keytruda in patients with advanced non-small cell lung cancer. This change aims to enhance site activation and support a competitive label if approved.

Nov 2, 2022

Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update • Arcus and Gilead Sciences are pursuing a broad development strategy for their anti-TIGIT antibody domvanalimab in lun

Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update -Arcus and Gilead Sciences are pursuing a broad development strategy for their anti-TIGIT antibody domvanalimab in lung cancer, which now includes three ongoing registrational Phase 3 t

Aug 3, 2022

Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update • Four registrational Phase 3 trials evaluating domvanalimab-based combinations are ongoing or expected to start by ye

Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update -Four registrational Phase 3 trials evaluating domvanalimab-based combinations are ongoing or expected to start by year-end; Arcus and Gilead Sciences continue to expand their late-sta

iTeos and GSK Mull Future of Anti-TIGIT Candidate After Genentech Flop

iTeos Therapeutics and GSK are assessing the future of their anti-TIGIT candidate, EOS-448, following Genentech's recent trial failures. Despite these setbacks, iTeos remains optimistic, citing encouraging data from their own clinical trials. The partnership with GSK is expected to enhance development capabilities, and iTeos is planning several new studies to evaluate EOS-448 in various cancer treatments.

May 9, 2022

Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study • In a third interim analysis for the randomized Phase 2

Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study -In a third interim analysis for the randomized Phase 2 ARC-7 study, both anti-TIGIT domvanalimab-containing arms continue

Feb 23, 2022

Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update • Presentations of randomized data for domvanalimab and etrumadenant in 1L PD-L1 high non-small cell lung

Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update -Presentations of randomized data for domvanalimab and etrumadenant in 1L PD-L1 high non-small cell lung cancer (NSCLC; ARC-7) and quemliclustat in pancreatic cancer (ARC-

Nov 8, 2021

Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab  Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to th

Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to that of zimberelimab alone in a second interim analysis of ARC-7, our

Aug 5, 2021

Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights All five clinical-stage molecules continue to advance with six ongoing randomized Phase 2 and Phase 3 studies in major t

Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights HAYWARD, Calif. - (BUSINESS WIRE) - August 5, 2021 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer ther

Jul 19, 2021

ARCUS CHIEF MEDICAL OFFICER TRANSITIONS TO ROLE AT GILEAD SCIENCES - Kartik Krishnan, M.D., Ph.D. and senior vice president will lead clinical development at Arcus

ARCUS CHIEF MEDICAL OFFICER TRANSITIONS TO ROLE AT GILEAD SCIENCES HAYWARD, Calif. - July 19, 2021 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bill Grossman M.D., Ph.D

May 5, 2021

Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights Continued to advance our portfolio of anti-TIGIT antibodies: On track for the ARC-7 interim analysis for domvanalimab in

Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights HAYWARD, Calif. - (BUSINESS WIRE) - May 5, 2021 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapie

Feb 24, 2021

Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights - Multiple key data read-outs expected for 2021, including the ARC-7 interim analysis in 2Q21 - Domvanalim

Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights HAYWARD, Calif. - (BUSINESS WIRE) - February 24, 2021 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-

Nov 5, 2020

Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates - Commenced 10-year highly strategic partnership with Gilead to deliver next-generation cancer therapies - Recently announced collabo

Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - November 5, 2020 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, toda

Aug 6, 2020

Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates Established a 10-year global partnership with Gilead to co-develop and co-commercialize next-generation cancer immunotherapies Stren

Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - August 6, 2020 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today

Jul 13, 2020

CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (

[***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this "Agreement") is dated as of May 27, 2020, by

May 5, 2020

Arcus Biosciences Announces First Quarter 2020 Financial Results and Corporate Updates - Preliminary data from randomized trials involving three molecules in 4Q20 o AB928, the first and only dual A 2a /A 2b adenosine rec

Arcus Biosciences Announces First Quarter 2020 Financial Results and Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - May 5, 2020 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today ann

Apr 7, 2020

Arcus's COVID-19 Statement Despite the ongoing situation with COVID-19, we continue to see relatively robust enrollment across our ongoing Arcus-sponsored studies at this time. Similar to other biotech and pharmaceutical

Arcus's COVID-19 Statement Despite the ongoing situation with COVID-19, we continue to see relatively robust enrollment across our ongoing Arcus-sponsored studies at this time. Similar to other biotech and pharmaceutical companies, we believe this pandemic may ultimately cause d

Mar 5, 2020

Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates - Advanced three molecules into randomized Phase 2 trials to evaluate Arcus's potential best-in-class therapies and hi

Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - March 5, 2020 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer the

Nov 5, 2019

Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates - Demonstrated best-in-class potential of AB928, a selective adenosine receptor antagonist that efficiently blocks both A 2a a

Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - November 5, 2019 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, t

Aug 6, 2019

Arcus Biosciences Announces Second Quarter 2019 Financial Results and Recent Corporate Updates - Progressing our lead program, AB928, a potential best-in-class dual A 2a /A 2b receptor antagonist, into multiple dose-expa

Arcus Biosciences Announces Second Quarter 2019 Financial Results and Recent Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - August 6, 2019 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, to

May 2, 2019

Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates Selected 150 mg for the dose expansion trial for AB928, the Company's dual A 2a /A 2b receptor antagonist, in combination with

Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates Hayward, CA. - (BUSINESS WIRE) - May 2, 2019 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, tod

Mar 5, 2019

Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates Ended 2018 with four molecules in clinical development, including AB928, the Company's dual A 2a R/A 2b R recep

Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates Hayward, CA. - (BUSINESS WIRE) - March 5, 2019 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer imm

Nov 8, 2018

Arcus Biosciences Announces Third Quarter 2018 Financial Results and Recent Corporate Updates - Three dose-escalation trials evaluating AB928, the Company's dual adenosine receptor antagonist, in combination with other a

Arcus Biosciences Announces Third Quarter 2018 Financial Results and Recent Corporate Updates AB154, an anti-TIGIT antibody - Hayward, CA. - (BUSINESS WIRE) - November [6], 2018 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creatin

Aug 6, 2018

Arcus Biosciences Announces Second Quarter 2018 Financial Results and Recent Corporate Updates - Initiated the Phase 1/1b program for AB928 combinations; Initial dose-escalation data for all four combinations expected in

Arcus Biosciences Announces Second Quarter 2018 Financial Results and Recent Corporate Updates Hayward, CA. - (BUSINESS WIRE) - August 6, 2018 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies,

Jul 12, 2018

Arcus Biosciences Announces that Taiho Pharmaceutical Has Exercised its Option to Develop and Commercialize AB928 in its Territories Hayward, CA. (BUSINESS WIRE)

Arcus Biosciences Announces that Taiho Pharmaceutical Has Exercised its Option to Develop and Commercialize AB928 in its Territories Hayward, CA. (BUSINESS WIRE) July 12, 2018 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating

May 9, 2018